Immunicon Corporation to Present at 2006 San Antonio Breast Cancer Symposium
Posters Address Attributes of Circulating Tumor Cells
HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM: IMMC) will present three posters at the 29th Annual San Antonio Breast Cancer Symposium, the premier breast cancer educational and scientific event, December 13-17 at the Georgia Henry B. Gonzalez Convention Center, San Antonio, Texas. The posters will address Immunicon’s cellular analysis of circulating tumor cells (CTC) in patients with metastatic breast cancer; CTCs in patients following adjuvant therapy; and the assessment of tumor cells in blood and bone marrow and gene signatures in primary breast cancer.
Presentations will include:
Circulating tumor cells in post-adjuvant breast cancer patients. (Abstract # 1011)
Almokadem S, Leitzel K, Harvey HA, Bannon E, Ali SM, Miller C, Terstappen LWWM, Doyle GV, Lipton A.
Session Info: Poster Session I: Detection and Diagnosis: Circulating Markers (5:00-7:00 PM)
Presentation Time: Thursday, December 14, 2006, 4:45 PM
Apoptosis and Bcl-2 expression in circulating tumor cells from women being treated for metastatic breast cancer. (Abstract # 5005)
Smerage JB, Doyle GV, Budd GT, Wicha MS, Schott AF, Blayney DW, Repollet M, Terstappen LWMM, Hayes DF.
Session Info: Poster Session V: Detection and Diagnosis: Marrow and Blood Micrometastases (5:00-7:00 PM)
Presentation Time: Saturday, December 16, 2006, 5:00 PM
Comparison of tumor cell levels in blood and bone marrow to hormone receptor status and gene signatures in tissue in patients undergoing surgical resection of primary breast cancer. (Abstract # 5008)
Frazier TG, Flynn MB, Sieling BA, Herman M, Rao C, Gross S, Pierce M, Doyle GV, Terstappen LWMM.
Session Info: Poster Session V: Detection and Diagnosis: Marrow and Blood Micrometastases (5:00-7:00 PM)
Presentation Time: Saturday, December 16, 2006, 5:00 PM
Following the conference, the Immunicon presentations will be posted on Immunicon’s Web site at
http://www.immunicon.com. The CellSearch™ Circulating Tumor Cell Kit to capture, count and characterize CTCs from a blood test, was developed by Immunicon and is marketed by Veridex, LLC, a Johnson & Johnson company. Veridex will exhibit at booth #219 during the meeting. For more about the 2006 San Antonio Breast Cancer Symposium, visit
http://www.sabcs.org/.
About Immunicon Corporation
For more information, please visit
www.immunicon.com.
Threaded Mode